Department of Molecular Pathology, Faculty of Life Sciences, Kumamoto University, 2-2-1 Honjo, Kumamoto 860-0811, Japan.
Am J Pathol. 2010 Mar;176(3):1542-51. doi: 10.2353/ajpath.2010.090720. Epub 2010 Jan 21.
A monocyte-chemoattracting factor is generated during blood coagulation and during clotting of platelet-rich plasma. This chemotactic factor attracts monocytes as a ligand of the C5a receptor; however, it inhibits C5a-induced neutrophil chemotaxis as an apparent receptor antagonist. The curious dual function of the serum monocyte chemotactic factor resembles that of the cross-linked homodimer of ribosomal protein S19 (RP S19). Indeed, the inactive precursor of the monocyte chemotactic factor was present in plasma, and the precursor molecule and RP S19, as well as the active form and the RP S19 dimer, were indistinguishable in terms of immunological reactivity and molecular size. Coagulation factor XIIIa, plasma transglutaminase, and membrane phosphatidylserine on the activated platelets were required for conversion of the precursor to the active form. In addition, the precursor molecule in plasma could be replaced by wild-type recombinant RP S19 but not by mutant forms of it. These results indicate that a molecule indistinguishable from RP S19 was present in plasma, and that the RP S19-like molecule was converted to the active form by a transglutaminase-catalyzed reaction on a scaffold that included the phosphatidylserine-exposed platelet membrane.
在血液凝固和富含血小板的血浆凝结过程中会产生一种单核细胞趋化因子。这种趋化因子作为 C5a 受体的配体吸引单核细胞; 然而,它作为一种明显的受体拮抗剂抑制 C5a 诱导的中性粒细胞趋化。血清单核细胞趋化因子的这种奇特的双重功能类似于核糖体蛋白 S19 (RP S19) 的交联同源二聚体。事实上,单核细胞趋化因子的无活性前体存在于血浆中,并且前体分子和 RP S19 以及活性形式和 RP S19 二聚体在免疫反应性和分子大小方面是不可区分的。凝血因子 XIIIa、血浆转谷氨酰胺酶和活化血小板上的膜磷脂酰丝氨酸是将前体转化为活性形式所必需的。此外,血浆中的前体分子可以被野生型重组 RP S19 取代,但不能被其突变形式取代。这些结果表明,血浆中存在与 RP S19 不可区分的分子,并且该 RP S19 样分子通过包括暴露于磷脂酰丝氨酸的血小板膜的支架上的转谷氨酰胺酶催化反应转化为活性形式。